Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2024-02-01 M&A Activity
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos rondt transactie af om Jyseleca® business over te dragen aan Alfasigma
M&A Activity Classification · 99% confidence The document is a press release dated January 31, 2024, announcing the 'successful completion of the transaction to transfer its Jyseleca® business to Alfasigma S.p.A.' It details financial considerations (€50 million upfront, milestones, royalties) and expected cost savings (€150 million to €200 million). This type of announcement, detailing a significant corporate transaction (asset transfer/sale) and its immediate financial impact, falls under the category of corporate actions related to financing or major structural changes. Since it is not a standard periodic report (10-K, IR, ER) or a specific announcement like a dividend or management change, it best fits the 'Capital/Financing Update' (CAP) category, as it involves a major cash transaction and restructuring of assets/operations. It is not a general regulatory filing (RNS) because it is highly specific to a corporate transaction.
2024-02-01 English
Galapagos rondt transactie af om Jyseleca® business over te dragen aan Alfasigma
M&A Activity Classification · 99% confidence The document is a press release dated January 31, 2024, announcing the successful completion of a transaction where Galapagos transferred its Jyseleca® business to Alfasigma. It details the financial terms (€50M upfront, milestones, royalties) and strategic implications for Galapagos (cost savings, focus on core platforms). This type of announcement, detailing a major corporate transaction like a business transfer or asset sale, most closely aligns with 'Capital/Financing Update' (CAP) as it involves significant financial restructuring and asset movement, or potentially 'Regulatory Filings' (RNS) if it were a generic disclosure. However, given the specific focus on the financial closure and transfer of a business unit, 'CAP' is the most appropriate fit among the specialized categories, as it relates to capital structure changes and major financial events, even if it's not a traditional financing round. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Since it is a formal announcement of a completed major transaction, it is classified as CAP.
2024-02-01 Dutch
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.
Regulatory Filings Classification · 95% confidence The document is a press release dated January 4, 2024, announcing a strategic collaboration agreement between Galapagos NV and Thermo Fisher Scientific regarding CAR-T product manufacturing in the US. It details a business development/partnership, which is not explicitly covered by most specific financial filing codes (like 10-K, ER, IR). It is a general corporate announcement regarding operations and strategy. Since it is a formal announcement of a significant business event (a strategic partnership) and does not fit the definitions for Earnings Release (ER), Interim Report (IR), Capital Update (CAP), or M&A (TAR), the most appropriate general category for a significant, non-standard corporate announcement is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements or significant news releases that don't fit elsewhere. Given the content is a press release announcing a partnership, RNS is the best fit among the provided options, as it is not a specific financial report or management/board change.
2024-01-05 Dutch
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.
Regulatory Filings Classification · 90% confidence The document is a press release dated January 4, 2024, announcing a strategic collaboration agreement between Galapagos and Thermo Fisher Scientific regarding CAR-T manufacturing. It details business developments, strategic execution, and includes standard forward-looking statements and contact information typical of a corporate announcement. This type of announcement, which details a significant business event but is not a full financial report (like 10-K or IR) or a formal regulatory filing like a proxy or dividend notice, most closely aligns with an Earnings Release (ER) if it were tied to quarterly results, or more generally, a Regulatory Filing (RNS) if it's a broad announcement. However, given the content focuses on a major business partnership and operational update, and it is not a formal SEC filing type listed (like 10-K or DEF 14A), it functions as a general corporate disclosure. Since it is not a transcript (CT), a management discussion (MDA), or a specific financial report, the most appropriate general category for a significant, non-standard corporate announcement that isn't a specific financial report is Regulatory Filings (RNS), which serves as a fallback for general regulatory announcements. It is not short enough to be a simple RPA.
2024-01-05 English
6-K Filing
Regulatory Filings
2024-01-05 English
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
Regulatory Filings Classification · 100% confidence The document is a press release dated January 3, 2024, announcing a strategic collaboration and licensing agreement between Galapagos NV and BridGene Biosciences regarding drug discovery in oncology. It details financial terms (upfront payments, milestones) and strategic rationale. This type of announcement, focusing on a specific corporate event like a partnership or major agreement, is typically classified as a general corporate announcement or regulatory filing. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is a formal announcement, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for significant, non-standard announcements, or potentially 'Capital/Financing Update' (CAP) if the focus was purely on funding, but the core is a business development deal. Given the options, RNS is the most appropriate catch-all for a major business development press release that isn't explicitly covered elsewhere. It is not short enough to be a simple RPA.
2024-01-04 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.